Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 100.27%.
Reported quarterly gross margin; no daily interpolation. Q1 FY2027 (2026-06-30): 0.00%.
GROSS MARGIN
100.27%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.90%
median of 563 covered companies
CURRENT VS SECTOR MEDIAN
+133.73%
vs the sector median at left
Market Cap
$666.85M
Gross Margin
78.85%
TTM Avg
82.67%
3Y Avg
82.58%
5Y Avg
83.02%
Market Cap
$683.14M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$649.13M
Gross Margin
91.05%
TTM Avg
-190849.07%
3Y Avg
-96132.87%
5Y Avg
-64176.88%
Market Cap
$638.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$713.99M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$715.49M
Gross Margin
60.02%
TTM Avg
59.55%
3Y Avg
55.45%
5Y Avg
55.70%
Market Cap
$716.11M
Gross Margin
-16.57%
TTM Avg
15.14%
3Y Avg
17.91%
5Y Avg
27.64%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $658.52M | 100.27% | 0.00% | 0.00% | 0.00% |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 78.85% | 82.67% | 82.58% | 83.02% |
| Annexon, Inc. (ANNX)vs › | $667.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $649.13M | 91.05% | -190849.07% | -96132.87% | -64176.88% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $713.99M | 0.00% | 0.00% | 0.00% | 0.00% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | 60.02% | 59.55% | 55.45% | 55.70% |
| Anteris Technologies Global Corp. (AVR)vs › | $716.11M | -16.57% | 15.14% | 17.91% | 27.64% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $719.62M | 100.00% | 141.50% | 99.31% | 94.19% |
Gross Margin
100.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-10-31 | 0.00% |
| 2020-06-30 | 23.15% |
| 2019-12-31 | 0.00% |
| 2019-07-31 | 0.00% |
| 2019-04-30 | 0.00% |
| 2019-01-31 | 0.00% |
| 2018-10-31 | 0.00% |
| 2018-07-31 | 0.00% |
| 2018-04-30 | 0.00% |
| 2018-01-31 | 0.00% |
| 2017-10-31 | 0.00% |
